Ainos signs VELDONA license deal with BioPhoenix worth up to $10 million
Bitget2026/09/24 12:00- Ainos signed a VELDONA license deal with BioPhoenix, setting a conditional collaboration framework valued at up to USD 10 million.
- BioPhoenix secured exclusive worldwide rights for Sjögren's disease and thrombocytopenia, covering development, manufacturing, and commercialization.
- BioPhoenix will fund and run assigned clinical and regulatory work, shifting late-stage development costs away from Ainos.
- Framework includes an upfront license fee, potential payments for up to 15 additional indications, and a one-time fee on BioPhoenix’s first sublicense.
- Ainos will receive 25% of applicable net sublicensing revenue, separate from license fees and any product supply revenue.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
